PURPOSE: To evaluate the impact of targeted DNA sequencing on selection of cancer therapy for patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: In this prospective, single-center, single-arm trial, patients with MBC were enrolled within 10 weeks of starting a new therapy. At enrollment, tumor samples underwent next-generation sequencing for any of 315 cancer-related genes to high depth (> 500×) using FoundationOne CDx. Sequencing results were released to providers at the time of disease progression, and physician treatment recommendations were assessed via questionnaire. We evaluated three prespecified questions to assess patients' perceptions of genomic testing. RESULTS: In all, 100 patients underwent genomic testing, with a median of five mutations (range, 0 to 13 mutations) detected per patient. Genomic testing revealed one or more potential therapies in 98% of patients (98 of 100), and 60% of patients (60 of 100) had one or more recommended treatments with level I/II evidence for actionability. Among the 94 genomic text reports that were released, there was physician questionnaire data for 87 patients (response rate, 92.6%) and 31.0% of patients (27 of 87) had treatment change recommended by their physician. Of these, 37.0% (10 of 27) received the treatment supported by genomic testing. We did not detect a statistically significant difference in time-to-treatment failure (log-rank P = .87) or overall survival (P = .71) among patients who had treatment change supported by genomic testing versus those who had no treatment change. For patients who completed surveys before and after genomic testing, there was a significant decrease in confidence of treatment success, specifically among patients who did not have treatment change supported by genomic testing (McNemar's test of agreement P = .001). CONCLUSION: In this prospective study, genomic profiling of tumors in patients with MBC frequently identified potential treatments and resulted in treatment change in a minority of patients. Patients whose therapy was not changed on the basis of genomic testing seemed to have a decrease in confidence of treatment success.
PURPOSE: To evaluate the impact of targeted DNA sequencing on selection of cancer therapy for patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: In this prospective, single-center, single-arm trial, patients with MBC were enrolled within 10 weeks of starting a new therapy. At enrollment, tumor samples underwent next-generation sequencing for any of 315 cancer-related genes to high depth (> 500×) using FoundationOne CDx. Sequencing results were released to providers at the time of disease progression, and physician treatment recommendations were assessed via questionnaire. We evaluated three prespecified questions to assess patients' perceptions of genomic testing. RESULTS: In all, 100 patients underwent genomic testing, with a median of five mutations (range, 0 to 13 mutations) detected per patient. Genomic testing revealed one or more potential therapies in 98% of patients (98 of 100), and 60% of patients (60 of 100) had one or more recommended treatments with level I/II evidence for actionability. Among the 94 genomic text reports that were released, there was physician questionnaire data for 87 patients (response rate, 92.6%) and 31.0% of patients (27 of 87) had treatment change recommended by their physician. Of these, 37.0% (10 of 27) received the treatment supported by genomic testing. We did not detect a statistically significant difference in time-to-treatment failure (log-rank P = .87) or overall survival (P = .71) among patients who had treatment change supported by genomic testing versus those who had no treatment change. For patients who completed surveys before and after genomic testing, there was a significant decrease in confidence of treatment success, specifically among patients who did not have treatment change supported by genomic testing (McNemar's test of agreement P = .001). CONCLUSION: In this prospective study, genomic profiling of tumors in patients with MBC frequently identified potential treatments and resulted in treatment change in a minority of patients. Patients whose therapy was not changed on the basis of genomic testing seemed to have a decrease in confidence of treatment success.
Authors: Janine Giese-Davis; Kate Collie; Kate M S Rancourt; Eric Neri; Helena C Kraemer; David Spiegel Journal: J Clin Oncol Date: 2010-12-13 Impact factor: 44.544
Authors: Maki Tanioka; Cheng Fan; Joel S Parker; Katherine A Hoadley; Zhiyuan Hu; Yan Li; Terry M Hyslop; Brandelyn N Pitcher; Matthew G Soloway; Patricia A Spears; Lynn N Henry; Sara Tolaney; Chau T Dang; Ian E Krop; Lyndsay N Harris; Donald A Berry; Elaine R Mardis; Eric P Winer; Clifford A Hudis; Lisa A Carey; Charles M Perou Journal: Clin Cancer Res Date: 2018-07-23 Impact factor: 12.531
Authors: Alexis D Bakos; Sadie P Hutson; Jennifer T Loud; June A Peters; Ruthann M Giusti; Mark H Greene Journal: Health Expect Date: 2008-09 Impact factor: 3.377
Authors: Veronica R Collins; Bettina Meiser; Obioha C Ukoumunne; Clara Gaff; D James St John; Jane L Halliday Journal: Genet Med Date: 2007-05 Impact factor: 8.822
Authors: Pedram Razavi; Matthew T Chang; Guotai Xu; Chaitanya Bandlamudi; Dara S Ross; Neil Vasan; Yanyan Cai; Craig M Bielski; Mark T A Donoghue; Philip Jonsson; Alexander Penson; Ronglai Shen; Fresia Pareja; Ritika Kundra; Sumit Middha; Michael L Cheng; Ahmet Zehir; Cyriac Kandoth; Ruchi Patel; Kety Huberman; Lillian M Smyth; Komal Jhaveri; Shanu Modi; Tiffany A Traina; Chau Dang; Wen Zhang; Britta Weigelt; Bob T Li; Marc Ladanyi; David M Hyman; Nikolaus Schultz; Mark E Robson; Clifford Hudis; Edi Brogi; Agnes Viale; Larry Norton; Maura N Dickler; Michael F Berger; Christine A Iacobuzio-Donahue; Sarat Chandarlapaty; Maurizio Scaltriti; Jorge S Reis-Filho; David B Solit; Barry S Taylor; José Baselga Journal: Cancer Cell Date: 2018-09-10 Impact factor: 31.743
Authors: Zachary L Skidmore; Alex H Wagner; Robert Lesurf; Katie M Campbell; Jason Kunisaki; Obi L Griffith; Malachi Griffith Journal: Bioinformatics Date: 2016-06-10 Impact factor: 6.937
Authors: Stacy W Gray; Elyse R Park; Julie Najita; Yolanda Martins; Lara Traeger; Elizabeth Bair; Joshua Gagne; Judy Garber; Pasi A Jänne; Neal Lindeman; Carol Lowenstein; Nelly Oliver; Lynette Sholl; Eliezer M Van Allen; Nikhil Wagle; Sam Wood; Levi Garraway; Steven Joffe Journal: Genet Med Date: 2016-02-11 Impact factor: 8.822
Authors: Angelo Paradiso; Giovanni Codacci-Pisanelli; Elisabetta Munzone; Hope S Rugo; Pierre Etienne Heudel Journal: Breast Care (Basel) Date: 2021-09-29 Impact factor: 2.268